Navigation Links
United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
Date:7/25/2013

trative expense

$

71,365$

53,25834.0

%General and administrative. The increase in general and administrative expense of $4.2 million for the quarter ended June 30, 2013 compared to the same quarter in 2012 was driven by increases in (1) salaries and operating expenses associated with the expansion of our business, (2) professional fees and (3) grants to non-affiliated, non-profit organizations that provide financial assistance to patients with pulmonary arterial hypertension. These increases were offset in part by a $6.8 million impairment charge on an acquired contract-based intangible we recognized during three months ended June 30, 2012.

Share-based compensation. The increase in share-based compensation of $13.7 million for the quarter ended June 30, 2013, compared to the same quarter in 2012, resulted from the appreciation in the price of our common stock.

Income TaxesThe provision for income taxes was $38.7 million for the quarter ended June 30, 2013, compared to $31.0 million for the same quarter in 2012. The estimated annual effective tax rate was 33 percent and 32 percent as of June 30, 2013 and 2012, respectively.

2013 Revenue GuidanceWe reaffirm our 2013 full-year revenue guidance for our three commercial products (Remodulin®, Tyvaso® and Adcirca®), as we continue to expect related revenues to fall within a range of 5% above or below $1.0 billion for 2013.

Earnings Before Non-Cash ChargesEarnings before non-cash charges is defined as net income, adjusted for the following non-cash charges, as applicable: (1) interest; (2) income taxes; (3) license fees; (4) depreciation and amortization; (5) impairment charges; and (6) share-based compensation (stock option, share tracking award and employee stock purchase plan expense).

A reconciliation of net income to earnings before non-cash charge
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. United Therapeutics Corporation to Announce Second Quarter 2013 Financial Results Before Market Open on Thursday, July 25, 2013
2. Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific
3. Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
4. Centre for Sight First in the United Kingdom to Utilize TrueVision® 3D Visualization During Femtosecond Laser Cataract Surgery
5. Prevagen® is the Number One Branded Memory Supplement in the United States
6. SPIE on Global Team Proposing ‘international Year of Light’ at United Nations
7. United Airlines and AltAir Fuels to Bring Commercial-Scale, Cost-Competitive Biofuels to Aviation Industry
8. Despite Lucentiss Recent Expanded Label for Diabetic Macular Edema, Avastin Remains the Preferred Intravitreal Therapy for Diabetic Macular Edema in the United States
9. Atlantic Peptides Teams Up with a United Kingdom Company to Offer cGMP Peptides and API
10. SoundConnect Announces Lync Release in the United States
11. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Global ... and premium industry insights on the global resorcinol industry. The report highlights the ... of vivid market scenarios and analysis of primary and secondary inputs from the ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... the detection and quantification of partially hydrolyzed gluten in foods, has been accepted ... adopted the method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ...
(Date:7/30/2015)... , July 30, 2015 AACC welcomed ... the 2015 AACC Annual Meeting & Clinical Lab ... July 26–30. The meeting showcased revolutionary advancements in ... ability of healthcare providers to diagnose patients quickly ... medical treatment. As of Wednesday, ...
(Date:7/30/2015)... France and Dallas, TX, USA (PRWEB) , ... ... ... of innovative nano and microsystems, has appointed Francois Vieillard as Sales & Marketing ... Marketing at executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2
... TORONTO, Sept. 23 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX: ... key terms with Toray,Industries Inc. of Japan to ... U.S. for Toraymyxin(TM), a therapeutic for the treatment ... the terms of the,agreement, the Company will seek ...
... InspireMD, Ltd.,announced today the enrollment of the first ... in acute myocardial infarction. The GUARD Study,(MGuard(TM) in ... safety and efficacy of MGuard(TM) in patients suffering ... were implanted,successfully with the MGuard(TM) Coronary Stent, in ...
... on Nano-Bio-Info-Cogno (NBIC) technologies and their interactions will ... Museum in Mountain View, California. The event ... participants to customize the event in a highly ... forecaster with over two decades experience exploring long-term ...
Cached Biology Technology:Spectral to bring anti-sepsis therapy to the U.S. market 2Spectral to bring anti-sepsis therapy to the U.S. market 3InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results 2InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results 3Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote 2Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote 3
(Date:7/31/2015)... La 10e Conférence internationale sur la ... le BGI du 22 au 25 octobre 2015 ... La conférence célèbre son 10e anniversaire ... est devenue l,une des réunions annuelles mondiales les ... c,est aussi la plus dynamique, la plus enthousiaste ...
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
(Date:7/27/2015)... JOSE, Calif. , July 27, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... ® touchscreen solution for its stylish smartwatch. ... for its proven reliability, low power and highly ... a wet finger. Huawei designers also required a ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... announced today its involvement in an expanded access ... treatment for phenylketonuria (PKU), a rare genetic metabolic ... children, can result in severe mental retardation. Currently, ... access program at Nationwide Childrens. Under an ...
... Society and other institutions declare that improvements in ... double the number of tigers currently existing in the ... in the most recent edition of the journal Biological ... the Indian subcontinentcomprising India, Bangladesh, Bhutan, and Nepal. It ...
... Boulder, CO, USA - Topics include: continental deformation ... Mars; correlation of 200-million-year-old rocks between Britain and ... mass extinctions; rock weathering in Canada,s Mackenzie River ... how stable continents split in the absence of ...
Cached Biology News:Nationwide Children's Hospital involved in expanded access program for treatment of PKU 2WCS study finds potential to double tiger numbers in South Asia 2November GEOLOGY and GSA TODAY Media Highlights 2November GEOLOGY and GSA TODAY Media Highlights 3November GEOLOGY and GSA TODAY Media Highlights 4November GEOLOGY and GSA TODAY Media Highlights 5November GEOLOGY and GSA TODAY Media Highlights 6November GEOLOGY and GSA TODAY Media Highlights 7November GEOLOGY and GSA TODAY Media Highlights 8November GEOLOGY and GSA TODAY Media Highlights 9November GEOLOGY and GSA TODAY Media Highlights 10
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
... Second Mitochondria Derived Activator of Caspase/DIABLO ... HEPES, pH 7.5 AVOID FREEZE/THAW CYCLES. Amino acid ... a carboxy terminal His•Tag ® sequence was ... . Smac/DIABLO is released along with cytochrome ...
... polyclonal to Decorin ( Abpromise ... Antigen: Synthetic peptide: IGPEVPDDRDFEPS ... acids 6-19 of Human Decorin (fragment ... proteoglycan II). Entrez ...
GLP expression profiling service on the Affymetrix platform. Starting material can be blood, tissue or RNA. 5 day turnaround. Standard and custom post analyses of microarray data available....
Biology Products: